Celltrion披露Remsima SC/Zymfentra上半年合计收入4562亿韩元，重申全年万亿韩元目标

Celltrion (068270.KS) said its subcutaneous infliximab formulation Remsima SC and its U.S. product Zymfentra generated a combined 456.2 billion won ($330 million) in revenue in the first half of this year, strengthening prospects that the product family will reach 1 trillion won in annual sales.
Remsima SC posted 356.7 billion won in revenue in Europe, South Korea and other markets during the first half, up 20.3% from a year earlier, Celltrion said on the 27th. Zymfentra, sold in the United States, surged 176.4% to 99.5 billion won. The figures show the U.S. market emerging as a new growth driver alongside steady expansion in Europe.
Remsima SC is also rapidly gaining prescriptions in Europe. Its share of the five largest European markets reached about 32% in the first quarter, an all-time high, according to pharmaceutical market research firm IQVIA. The product held 49% in Germany, 35% in France and 31% in Italy.
A dual formulation strategy — supplying both the intravenous version, Remsima, and the subcutaneous Remsima SC — is contributing to growth. Because patients can choose between the two formulations depending on their condition and treatment setting, the approach allows existing Remsima patients to be moved onto Remsima SC for maintenance therapy.
In the United States, Zymfentra has entered a phase of substantial growth. Celltrion is focusing on expanding prescriptions by drawing on local insurance reimbursement coverage and its distribution and sales networks. The company also plans to launch the drug in Japan in 2027 and to expand sales territories in Latin America.
Celltrion said it aims to build the Remsima SC product family into its second product to reach 1 trillion won in annual sales after Remsima, based on wider prescribing in Europe, U.S. revenue growth and entry into new markets.